RYAN BROWN: Open Payments
NPI 1760826275 · MILLSBORO, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$907 in 50 payments from 15 companies in 2025. Trend: 2023 $779 · 2024 $996 · 2025 $907
Food & beverage: $907
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $161 |
| Merck Sharp & Dohme LLC | 5 | $121 |
| PFIZER INC. | 5 | $91 |
| Novo Nordisk Inc | 5 | $89 |
| Amgen Inc. | 4 | $84 |
| Lilly USA, LLC | 3 | $64 |
| GlaxoSmithKline, LLC. | 3 | $55 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 3 | $39 |
| Aimmune Therapeutics, Inc. | 1 | $36 |
Products named: GARDASIL 9, EVENITY, VRAYLAR, MOUNJARO, ELIQUIS, Ozempic, XIFAXAN, LAGEVRIO.
Industry payments across DE — which companies pay providers there.
